(Albany, US) DelveInsight has launched a new report on Metabolic Acidosis Pipeline Insight – 2020.
“Metabolic Acidosis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Metabolic Acidosis market. A detailed picture of the Metabolic Acidosis pipeline landscape is provided, which includes the disease overview and Metabolic Acidosis treatment guidelines.
The assessment part of the report embraces in-depth Metabolic Acidosis commercial assessment and clinical assessment of the Metabolic Acidosis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metabolic Acidosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Request for Sample Pages : https://www.delveinsight.com/sample-request/metabolic-acidosis-market
Some of the key companies working on Metabolic Acidosis are:
- Tricida
- Advicenne Pharma
And Many Others.
The launch of the emerging therapies is expected to significantly impact the Metabolic Acidosis treatment scenario in the upcoming years:-
- Veverimer (TRC101)
- ADV7103
And Many Others.
Request for Sample Pages : https://www.delveinsight.com/sample-request/metabolic-acidosis-market
Metabolic Acidosis (MA) is a severe electrolyte disorder characterized by an imbalance in the body’s acid–base balance. Metabolic acidosis can lead to acidemia—state of low blood pH, i.e. when arterial blood pH falls below 7.37—which is a result of acidosis—the process in the body that causes a low pH in blood and tissues.
Generally, MA can be caused by three major mechanisms:
- Increased acid production
- Bicarbonate loss, and
- Decreased renal acid excretion.
Metabolic acidosis can last minutes to several days (acute metabolic acidosis), which often occurs during serious illnesses or hospitalizations.
Symptoms of MA are not specific and may include palpitations, headache, altered mental status such as severe anxiety due to hypoxia, decreased visual acuity, nausea, vomiting, abdominal pain, altered appetite and weight gain, muscle weakness, bone pain, and joint pain. People with acute metabolic acidosis may exhibit deep, rapid breathing called Kussmaul respirations which is classically associated with diabetic ketoacidosis.
“As per DelveInsight insights, Italy has consistently shown lowest prevalent population among EU5 for MA.”
Request for Sample Pages : https://www.delveinsight.com/sample-request/metabolic-acidosis-market
1. Report Introduction
2. Metabolic Acidosis
2.1. Overview
2.2. History
2.3. Metabolic Acidosis Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Metabolic Acidosis Diagnosis
2.6.1. Diagnostic Guidelines
3. Metabolic Acidosis Current Treatment Patterns
3.1. Metabolic Acidosis Treatment Guidelines
4. Metabolic Acidosis – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Metabolic Acidosis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Metabolic Acidosis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Metabolic Acidosis Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Metabolic Acidosis Late Stage Products (Phase-III)
7. Metabolic Acidosis Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metabolic Acidosis Discontinued Products
13. Metabolic Acidosis Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Metabolic Acidosis Key Companies
15. Metabolic Acidosis Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Metabolic Acidosis Unmet Needs
18. Metabolic Acidosis Future Perspectives
19. Metabolic Acidosis Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
